Lake Bluff, Nov 6th, 2003 / PRNewswire / -- Coremed, Inc., has announced the successful development of Alvair™, a pulmonary-delivered insulin formulation that is based on an animal study. It termed the results efficacious and clean - with "no residue."

Ever since 1994, Coremed, Inc., has been exclusively dedicated to the development of oral insulin. The results of its intensive pre-clinical biological trials of oral insulin have been presented around the world.

Coremed's preliminary animal data were announced by Frank K. Leung, M.D., F.A.C.E., a Harvard-trained endocrinologist and researcher, who is director of Coremed's laboratory.

Dr. Leung said the preliminary data show that Alvair™ has equal efficacy as subcutaneous insulin injection. Marked efficacy was achieved as low as 0.1 u/kg. doses with sustained steady action over many hours. The data variations were minimal and its glucodynamic profiles were uniform.

Alvair™'s insulin bioavailability is the highest of any current reported literature.

The lungs are exquisitely sensitive to particles, whether they are inert or biologically inactive. Any residues, including insulin itself, can be potentially harmful to the lungs. The current leading inhaled insulin technology is approximately one tenth of the efficacy of injection. Its glucose-lowering action is relatively short-lived.

Alvair™ is an extremely efficient formulation requiring very low insulin concentration in the order of sub-units, compared to the requirement of 250-500 units/ml. concentration in some of the leading inhaled insulin formulations, Dr. Leung said.

"Although we are a late comer in this area, our technology is really far ahead of the current leaders," he said. "However, we still have more work to do."

The major advantages of Alvair™'s efficacy, "cleaniness," glucodynamic profiles and extremely low manufacturing costs will enable a pharmaceutical company to develop a leading product without significant investment in sophisticated insulin manufacturing and biological facilities, Dr. Leung added.

About Coremed

Founded in 1994, Coremed, Inc., a Lake Bluff, Ill.-based specialty research laboratory, is developing transmucosal insulin based on its proprietary technology, for the treatment of diabetes mellitus. For more information, visit its web site www.coremedusa.com.